Melanoma Trial, Recruiting NCT04493723 Sponsor: The Christie NHS Foundation Trust Condition: Melanoma
Back to Melanoma

Melanoma Trial, Recruiting

NCT04493723
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 16 years or older
  • People who are willing and able to give written consent to take part
  • People who have been diagnosed with locally advanced or metastatic melanoma (also called stage III or stage IV melanoma)
  • People who have a tumour that a doctor can safely access for a biopsy, either using imaging guidance or surgery (this applies to the part of the study involving biopsies)
  • People whose blood count and clotting test results fall within acceptable ranges (this applies to the part of the study involving biopsies)

Who may not be able to join:

  • People who are unable to give informed consent to participate
  • People with a significant history of bleeding or clotting disorders — though people taking blood-thinning medications may still be considered if those medications can be safely managed around biopsy and blood sample procedures (confirm with trial site)
  • People with a history of HIV, Hepatitis B, Hepatitis C, or other infectious diseases that can be passed between people
  • People with any condition where taking research biopsies or blood samples could increase the risk of complications for the patient or the research team, including people in higher-risk groups such as intravenous drug users

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lorigan, Prof, University of Manchester

Phone: 0161 446 3472

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
The Christie NHS Foundation Trust
Registry
ClinicalTrials.gov
Start date
14 November 2018
Est. completion
1 July 2034

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

The number of patients who consent to have additional samples taken for research purposes and the number of research samples collected.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov